Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2012

01-03-2012 | Original Article

Prediction of long-term outcome in glycine encephalopathy: a clinical survey

Authors: Julia B. Hennermann, Jeanne-Marie Berger, Ulrike Grieben, Gunter Scharer, Johan L. K. Van Hove

Published in: Journal of Inherited Metabolic Disease | Issue 2/2012

Login to get access

Abstract

Objective

Glycine encephalopathy (GE) is a rare autosomal recessive inborn error of glycine degradation resulting in severe encephalopathy with ensuing poor outcome. Attenuated variants with a significantly better outcome have been reported. Early prediction of long-term outcome is not yet possible.

Methods

We compared the clinical and biochemical features of 45 children, each with a different course of the disease, to help determine predictors of long-term outcome.

Results

The most common presenting symptoms were hypotonia, seizures, and coma. In this study, 85% of the patients presented within the first week of life, and 15% presented after the neonatal period up to the age of 12 months. Developmental progress was made by 19% of those children presenting during the neonatal period and by 50% of those presenting in infancy. Initial CSF and plasma glycine concentrations were not useful in differentiating severe and attenuated outcome. A severe outcome was significantly associated with early onset of spasticity, frequent hiccupping, EEG burst-suppression or hypsarrhythmia patterns, microcephaly, and congenital or cerebral malformations, e.g. corpus callosum hypoplasia. An attenuated outcome was significantly associated with hyperactivity and choreiform movement disorders. We describe a severity score which facilitates the prediction of the outcome in patients with GE.

Conclusion

Prediction of the outcome of GE may be facilitated by recognizing selected clinical parameters and early neuroimaging findings.
Appendix
Available only for authorised users
Literature
go back to reference Applegarth DA, Toone JR (2001) Nonketotic hyperglycinemia (glycine encephalopathy): laboratory diagnosis. Mol Genet Metab 74:139–146PubMedCrossRef Applegarth DA, Toone JR (2001) Nonketotic hyperglycinemia (glycine encephalopathy): laboratory diagnosis. Mol Genet Metab 74:139–146PubMedCrossRef
go back to reference Applegarth DA, Toone JR (2004) Workshop report. Glycine encephalopathy (nonketotic hyperglycinemia): review and update. J Inherit Metab Dis 27:417–422PubMedCrossRef Applegarth DA, Toone JR (2004) Workshop report. Glycine encephalopathy (nonketotic hyperglycinemia): review and update. J Inherit Metab Dis 27:417–422PubMedCrossRef
go back to reference Applegarth DA, Toone JR, Lowry RB (2000) Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics 105:e10PubMedCrossRef Applegarth DA, Toone JR, Lowry RB (2000) Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics 105:e10PubMedCrossRef
go back to reference Boneh A, Degani Y, Harari M (1996) Prognostic clues and outcome of early treatment of nonketotic hyperglycinemia. Pediatr Neurol 15:137–141PubMedCrossRef Boneh A, Degani Y, Harari M (1996) Prognostic clues and outcome of early treatment of nonketotic hyperglycinemia. Pediatr Neurol 15:137–141PubMedCrossRef
go back to reference Boneh A, Allan S, Mendelson D, Spriggs M, Gillam LH, Korman SH (2008) Clinical, ethical, and legal considerations in the treatment of newborns with non-ketotic hyperglycinemia. Mol Genet Metab 94:143–147PubMedCrossRef Boneh A, Allan S, Mendelson D, Spriggs M, Gillam LH, Korman SH (2008) Clinical, ethical, and legal considerations in the treatment of newborns with non-ketotic hyperglycinemia. Mol Genet Metab 94:143–147PubMedCrossRef
go back to reference Breitkreutz J, Bornhöft M, Wöll F, Kleinebudde P (2003a) Pediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder. Eur J Pharm Biopharm 56:247–253PubMedCrossRef Breitkreutz J, Bornhöft M, Wöll F, Kleinebudde P (2003a) Pediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder. Eur J Pharm Biopharm 56:247–253PubMedCrossRef
go back to reference Breitkreutz J, El-Saleh F, Kiera C, Kleinebudde P, Wiedey W (2003b) Pediatric drug formulations of sodium benzoate: II. Coated granules with a lipophilic binder. Eur J Pharm Biopharm 56:255–260PubMedCrossRef Breitkreutz J, El-Saleh F, Kiera C, Kleinebudde P, Wiedey W (2003b) Pediatric drug formulations of sodium benzoate: II. Coated granules with a lipophilic binder. Eur J Pharm Biopharm 56:255–260PubMedCrossRef
go back to reference Brunel-Guitton C, Casey B, Coulter-Mackie M et al. (2011) Late-onset nonketotic hyperglycinemia caused by a novel homozygous missense mutation in the GLDC gene. Mol Genet Metab 103:193–196PubMedCrossRef Brunel-Guitton C, Casey B, Coulter-Mackie M et al. (2011) Late-onset nonketotic hyperglycinemia caused by a novel homozygous missense mutation in the GLDC gene. Mol Genet Metab 103:193–196PubMedCrossRef
go back to reference Busanello EN, Moura AP, Viegas CM et al. (2010) Neurochemical evidence that glycine induces bioenergetical dysfunction. Neurochem Int 56:948–954PubMedCrossRef Busanello EN, Moura AP, Viegas CM et al. (2010) Neurochemical evidence that glycine induces bioenergetical dysfunction. Neurochem Int 56:948–954PubMedCrossRef
go back to reference Carson NAJ (1982) Non-ketotic hyperglycinemia – a review of 70 patients. J Inheret Metab Dis 5(Suppl 2):126–128CrossRef Carson NAJ (1982) Non-ketotic hyperglycinemia – a review of 70 patients. J Inheret Metab Dis 5(Suppl 2):126–128CrossRef
go back to reference Dinopoulos A, Matsubara Y, Kure S (2005) Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab 86:61–69PubMedCrossRef Dinopoulos A, Matsubara Y, Kure S (2005) Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab 86:61–69PubMedCrossRef
go back to reference Fletcher JM, Bye AM, Nayannar V, Wilcken B (1995) Non-ketotic hyperglycinaemia presenting as pachygyria. J Inherit Metab Dis 18:665–668PubMedCrossRef Fletcher JM, Bye AM, Nayannar V, Wilcken B (1995) Non-ketotic hyperglycinaemia presenting as pachygyria. J Inherit Metab Dis 18:665–668PubMedCrossRef
go back to reference Hall DA, Ringel SP (2004) Adult nonketotic hyperglycinemia (NKH) crisis presenting as severe chorea and encephalopathy. Mov Disord 19:485–486PubMedCrossRef Hall DA, Ringel SP (2004) Adult nonketotic hyperglycinemia (NKH) crisis presenting as severe chorea and encephalopathy. Mov Disord 19:485–486PubMedCrossRef
go back to reference Hamosh A, Johnston MV (2001) The metabolic and molecular bases of inherited disease. In: Sciver CR, Beaudet AL, Sly WS, Valle D (eds) Nonketotic hyperglycinemia, 8th edn. McGraw-Hill, New York, pp 2065–2078 Hamosh A, Johnston MV (2001) The metabolic and molecular bases of inherited disease. In: Sciver CR, Beaudet AL, Sly WS, Valle D (eds) Nonketotic hyperglycinemia, 8th edn. McGraw-Hill, New York, pp 2065–2078
go back to reference Hamosh A, Mcdonald JW, Valle D, Francomano CA, Niedermeyer E, Johnston MV (1992) Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 132:709–713 Hamosh A, Mcdonald JW, Valle D, Francomano CA, Niedermeyer E, Johnston MV (1992) Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 132:709–713
go back to reference Harty TP, Rogawski MA (2000) Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 39:47–55PubMedCrossRef Harty TP, Rogawski MA (2000) Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 39:47–55PubMedCrossRef
go back to reference Hennermann JB (2006) Clinical variability in glycine encephalopathy. Future Neurol 1:621–630CrossRef Hennermann JB (2006) Clinical variability in glycine encephalopathy. Future Neurol 1:621–630CrossRef
go back to reference Hoover-Fong JE, Shah S, Van Hove JLK, Applegarth D, Toone J, Hamosh A (2004) Natural history of nonketotic hyperglycinemia in 65 patients. Neurology 63:1847–1853PubMed Hoover-Fong JE, Shah S, Van Hove JLK, Applegarth D, Toone J, Hamosh A (2004) Natural history of nonketotic hyperglycinemia in 65 patients. Neurology 63:1847–1853PubMed
go back to reference Jones CM, Smith M, Henderson MJ (2006) Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism. Ann Clin Biochem 43:63–66PubMedCrossRef Jones CM, Smith M, Henderson MJ (2006) Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism. Ann Clin Biochem 43:63–66PubMedCrossRef
go back to reference Korman SH, Boneh A, Ichinohe A, Kojima K, Sato K, Ergaz Z, Gomori JM, Gutman A, Kure S (2004) Persistent NKH with transient or absent symptoms and a homozygous GLDC mutation. Ann Neurol 56:139–143PubMedCrossRef Korman SH, Boneh A, Ichinohe A, Kojima K, Sato K, Ergaz Z, Gomori JM, Gutman A, Kure S (2004) Persistent NKH with transient or absent symptoms and a homozygous GLDC mutation. Ann Neurol 56:139–143PubMedCrossRef
go back to reference Kure S, Ichinohe A, Kojima K, Sato K, Kizaki Z, Inoue F, Yamanaka C, Matsubara Y (2004) Mild variant of nonketotic hyperglycinemia with typical neonatal presentations: mutational and in vitro expression analyses in two patients. J Pediatr 144:827–829PubMed Kure S, Ichinohe A, Kojima K, Sato K, Kizaki Z, Inoue F, Yamanaka C, Matsubara Y (2004) Mild variant of nonketotic hyperglycinemia with typical neonatal presentations: mutational and in vitro expression analyses in two patients. J Pediatr 144:827–829PubMed
go back to reference Morrison PF, Sankar R, Shields WD (2006) Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. Pediatr Neurol 35:356–358PubMedCrossRef Morrison PF, Sankar R, Shields WD (2006) Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. Pediatr Neurol 35:356–358PubMedCrossRef
go back to reference Nguyen L, Rigo J-M, Rocher V et al. (2001) Neurotransmitters as early signal for central nervous system development. Cell Tissue Res 305:187–202PubMedCrossRef Nguyen L, Rigo J-M, Rocher V et al. (2001) Neurotransmitters as early signal for central nervous system development. Cell Tissue Res 305:187–202PubMedCrossRef
go back to reference Schmitt B, Steinmann B, Gitzelmann R, Thun-Hohenstein L, Mascher H, Dumermuth G (1993) Nonketotic hyperglycinemia: clinical and electrophysiologic effects of dextromethorphan, an antagonist of the NMDA receptor. Neurology 43:421–424PubMed Schmitt B, Steinmann B, Gitzelmann R, Thun-Hohenstein L, Mascher H, Dumermuth G (1993) Nonketotic hyperglycinemia: clinical and electrophysiologic effects of dextromethorphan, an antagonist of the NMDA receptor. Neurology 43:421–424PubMed
go back to reference Tada K, Kure S (1993) Non-ketotic hyperglycinemia: molecular lesion, diagnosis, and pathophysiology. J Inherit Metab Dis 16:691–703PubMedCrossRef Tada K, Kure S (1993) Non-ketotic hyperglycinemia: molecular lesion, diagnosis, and pathophysiology. J Inherit Metab Dis 16:691–703PubMedCrossRef
go back to reference Van Hove JLK, Kishnani P, Muenzer J et al. (1995) Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia. Am J Med Genet 59:444–453PubMedCrossRef Van Hove JLK, Kishnani P, Muenzer J et al. (1995) Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia. Am J Med Genet 59:444–453PubMedCrossRef
go back to reference Van Hove JLK, Kishnani PS, Demaerel P et al. (2000) Acute hydrocephalus in nonketotic hyperglycinemia. Neurology 54:754–756PubMed Van Hove JLK, Kishnani PS, Demaerel P et al. (2000) Acute hydrocephalus in nonketotic hyperglycinemia. Neurology 54:754–756PubMed
go back to reference Van Hove JLK, Vande Kerckhove K, Hennermann JB et al. (2005) Benzoate treatment and the glycine index in nonketotic hyperglycinemia. J Inherit Metab Dis 28:651–663PubMedCrossRef Van Hove JLK, Vande Kerckhove K, Hennermann JB et al. (2005) Benzoate treatment and the glycine index in nonketotic hyperglycinemia. J Inherit Metab Dis 28:651–663PubMedCrossRef
go back to reference Wolff JA, Kulovich S, Yu AL, Qiao CN, Nyhan WL (1986) The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia. Am J Dis Child 140:596–602PubMed Wolff JA, Kulovich S, Yu AL, Qiao CN, Nyhan WL (1986) The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia. Am J Dis Child 140:596–602PubMed
go back to reference Yis U, Kurul SH, Dirik E (2009) Nonketotic hyperglycinemia and acquired hydrocephalus. Pediatr Neurol 40:138–140PubMedCrossRef Yis U, Kurul SH, Dirik E (2009) Nonketotic hyperglycinemia and acquired hydrocephalus. Pediatr Neurol 40:138–140PubMedCrossRef
Metadata
Title
Prediction of long-term outcome in glycine encephalopathy: a clinical survey
Authors
Julia B. Hennermann
Jeanne-Marie Berger
Ulrike Grieben
Gunter Scharer
Johan L. K. Van Hove
Publication date
01-03-2012
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 2/2012
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-011-9398-1

Other articles of this Issue 2/2012

Journal of Inherited Metabolic Disease 2/2012 Go to the issue